Sotorasib + Cetuximab (CodeBreaK 300, KRAS G12C+ mCRC)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-SOTORASIB DRUG-CETUXIMAB |
|---|
| ID | REG-SOTORASIB-CETUXIMAB-CRC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-27 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-COLON-2024 SRC-NCCN-COLON-2025 |
Notes
CodeBreaK 300 Phase III (2024): KRAS G12C+ chemo-refractory mCRC, sotorasib 960 mg + cetuximab vs investigator-choice chemo (TAS-102 / regorafenib). mPFS 5.6 vs 2.2 mo (HR 0.49); ORR 26%. Mechanistic rationale: KRAS G12C inhibition triggers EGFR feedback reactivation; concurrent EGFR blockade prevents bypass. FDA approval 2024 for combination. Note: in NSCLC sotorasib monotherapy is approved 2L+; in CRC the combination with cetuximab is the standard.
Used By
Indication
IND-CRC-METASTATIC-2L-KRAS-G12C-SOTORASIB-CETUXIMAB- IND-CRC-METASTATIC-2L-KRAS-G12C-SOTORASIB-CETUXIMAB